The hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/c-MET) receptor tyrosine kinase (RTK) pathway plays a pleotropic role in cell proliferation, migration, invasion, angiogenesis and survival. Although it has critical physiological functions in embryonic development and tissue repair, this signaling cascade is frequently deregulated in a wide range of tumors. Aberrant HGF/c-MET signaling, driven by various mechanisms, including constitutive activation and over-expression, has multifunctional effects in oncogenesis and is implicated in the acquisition of an aggressive phenotype with metastatic potential. The central role of c-MET activity in cancer progression, as well as disparities between quiescent HGF/c-MET signaling in normal tissue and overexpression in tumor may provide a degree of tumor selectivity for therapeutic intervention, making HGF or c-MET inhibition an attractive proposition in oncology. This review focuses on the underlying oncogenic role of aberrant HGF/c-MET signaling in malignant progression, as well as recent preclinical and clinical data on the different strategies employed in inhibiting HGF/c-MET function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/138945011798829348 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coptisine inhibits esophageal carcinoma growth by modulating pyroptosis via inhibition of HGF/c-Met signaling.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Esophageal carcinoma is a highly prevalent malignancy worldwide. The present study aimed to investigate the mechanism by which the natural compound coptisine affects pyroptosis in esophageal squamous cell carcinoma (ESCC). The expression of c-Met in ESCC patients was assessed by immunohistochemical analysis of tissue microarrays.
View Article and Find Full Text PDFRole of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Cancer Immunol Immunother
January 2025
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Most of advanced non-small cell lung cancer (NSCLC) patients will experience tumor progression with immunotherapy (IO). Preliminary data suggested an association between high plasma HGF levels and poor response to IO in advanced NSCLC. Our study aimed to evaluate further the role of the HGF/MET pathway in resistance to IO in advanced NSCLC.
View Article and Find Full Text PDFComprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers.
Crit Rev Oncol Hematol
December 2024
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 GuoXue Xiang, Chengdu, Sichuan 610041, China. Electronic address:
Article Synopsis
- Targeted therapy marks a significant advancement in medicine, beginning with the FDA's approval of bevacizumab for colorectal cancer in 2004, shifting focus from traditional chemotherapy.
- Over the past two decades, new therapeutic targets like EGF/EGFR and VEGF/VEGFR have emerged rapidly, with previously undruggable targets, such as RAS, now being investigated.
- Despite these advances, the effectiveness of targeted therapy can vary greatly, prompting a review of key signaling pathways, recent developments, and future directions in treating gastrointestinal cancers.
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.
Int J Mol Sci
August 2024
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Non-small cell lung cancer (NSCLC) is characterized by several molecular alterations that contribute to its development and progression. These alterations include the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), human epidermal growth factor receptor 2 (HER2), and mesenchymal-epithelial transition factor (c-MET). Among these, the hepatocyte growth factor (HGF)/c-MET signaling pathway plays a crucial role in NSCLC.
View Article and Find Full Text PDFResearch progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review.
World J Gastrointest Oncol
August 2024
Department of Oncology, People's Hospital of Chongqing Hechuan, Chongqing 401520, China.
Article Synopsis
- Hepatocyte growth factor (HGF) and its receptor c-Met are important for understanding and treating gastric cancer (GC), a common type of cancer.
- The HGF/c-Met signaling pathway helps cancer cells grow, move, and spread, making it a key focus for new treatments.
- This review looks at the latest research on how HGF/c-Met works in GC and suggests new ways to target this pathway for better treatment options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!